Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

NCT02397694 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

98

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-1 Infection

Interventions

DRUG: BIC
DRUG: F/TAF
DRUG: DTG
DRUG: BIC Placebo
DRUG: DTG Placebo
DRUG: B/F/TAF

Sponsor

Gilead Sciences